It's the fastest-rising peptide search term in the world — an experimental Eli Lilly drug people are already chasing online before it exists as a medicine. Here's what retatrutide actually is, what the trials do and don't show, and why in 2026 there is no approved, legitimate way to obtain it.
Retatrutide (developer code LY-3437943) is an investigational peptide from Eli Lilly being studied for obesity. It's a single molecule engineered to act on three receptors at once — GLP-1, GIP, and glucagon — which is why it's often called a "triple agonist" or, informally, "triple-G." GLP-1 and GIP affect insulin response and satiety; adding glucagon-receptor activity is thought to increase energy expenditure on top of reducing appetite.
The honest headline: retatrutide is not a medicine yet. It is an experimental drug in clinical trials. It is not a supplement, not approved, and not something a clinician can legitimately prescribe in 2026. Everything below is reported research, not a product you can use.
Retatrutide is not an FDA-approved drug, and the nuance matters:
Want the live picture? Our regulatory-status tracker shows exactly where retatrutide and other peptides stand right now, with the dated primary sources.
The evidence here is unusual for a peptide this hyped: it comes from real, large, company-run clinical trials, not just anecdote. In the published Phase 2 trial (Jastreboff et al., NEJM, 2023), adults with obesity on the highest dose lost up to roughly 24% of body weight over 48 weeks. In 2026, Eli Lilly reported Phase 3 data describing mean weight loss of around 28% at 80 weeks on the top dose.
Those are striking numbers — but two cautions apply. First, these are trial results under controlled conditions, not outcomes from grey-market vials of unknown content. Second, the long-term safety profile is still being established; reported side effects are mostly gastrointestinal (nausea, vomiting, diarrhea) and rise with dose. Impressive Phase 2/3 efficacy does not make an unapproved, unregulated online product safe to use.
Because retatrutide is investigational, there is no approved or prescribable dose. In Eli Lilly's clinical trials it was given as a once-weekly subcutaneous injection, escalated gradually over time to as much as ~12 mg per week on the highest study arm. It is not available as an approved product, so any figure you see comes from those trials or the wider community rather than a standardized regimen. To be clear: these are not approved or standardized doses — they reflect what clinics and the wider community commonly report using today, shared for education, not medical advice. Any real decision about an obesity medicine belongs with a licensed provider using approved options.
Injectable peptides are often shipped as a freeze-dried (lyophilized) powder that must be reconstituted with bacteriostatic water before use. The math — concentration and the volume to draw — trips a lot of people up, and a misplaced decimal in micrograms is a 1,000× error. That's what our free tool is for:
In trials, the most common adverse effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — and they increase with higher doses. Trials also reported mild heart-rate increases and, as with all GLP-1-class drugs, attention to risks such as pancreatitis and gallbladder issues. Critically, long-term safety in the real world is not yet established, and none of that trial monitoring exists for grey-market product. Because anything sold online is research-use-only and unregulated, purity, sterility, dose accuracy, and even whether the vial contains retatrutide at all are unknowns — which is why sourcing claims should be treated with deep skepticism.
If weight loss is the goal, the responsible path runs through a licensed provider who can discuss approved options and your situation — not a checkout page for an experimental drug. Questions worth asking any source making "retatrutide" claims: Is this an approved product? (No — so why is it being sold?) Is there third-party testing and a certificate of analysis? What is the actual regulatory status? This isn't legal or medical advice — it's the baseline diligence any unapproved, investigational substance demands.
No. Semaglutide (Ozempic/Wegovy) is a single GLP-1 agonist and tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist — both are FDA-approved. Retatrutide adds a third target, the glucagon receptor, and is still investigational and not approved.
There is no confirmed approval date. It is in Phase 3 trials in 2026. Approval timelines depend on full trial results and FDA review, and we don't speculate on dates — check the regulatory tracker for the current status.
No. It's a peptide — a chain of amino acids engineered to act on three metabolic receptors — not an anabolic steroid or hormone.
You can't, legitimately — there is no approved product. We don't sell peptides and we don't direct consumers to buy unapproved or investigational substances. Anything advertised as "retatrutide for sale" is unverified, research-use-only material.
Educational information only. Not medical, legal, or regulatory advice, not a dosing, treatment, or efficacy claim, and not a recommendation to obtain or use any substance. Many peptides are not FDA-approved; some are labeled research-use-only ("not for human use"). Regulatory status changes frequently — verify independently and consult a licensed provider before any health decision. Published by Health Pro Distributors. © 2026.